Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
Grace Therapeutics (Nasdaq: GRCE) announced that CEO Prashant Kohli will present at the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025 in New York.
Grace is a late-stage biopharma advancing GTx-104, an injectable nimodipine formulation for IV infusion to treat aneurysmal subarachnoid hemorrhage (aSAH) patients. The Alpha Select Conference is invitation-only; attending companies are selected for being smaller, underfollowed public companies with potential to scale. Investors seeking a meeting should contact their Craig-Hallum representative.
Grace Therapeutics (Nasdaq: GRCE) ha annunciato che il CEO Prashant Kohli interverrà alla 16a Alpha Select Conference di Craig-Hallum il 18 novembre 2025 a New York.
Grace è una biopharma di late-stage che avanza GTx-104, una formulazione injectable di nimodipina per infusione IV per trattare i pazienti con emorragia subaracnoidea aneurismatiche (aSAH). La Alpha Select Conference è su invito; le aziende partecipanti sono selezionate perché sono aziende quotate di piccole dimensioni, poco seguite con potenziale di crescita. Gli investitori interessati a un incontro dovrebbero contattare il loro rappresentante Craig-Hallum.
Grace Therapeutics (Nasdaq: GRCE) anunció que el CEO Prashant Kohli presentará en la 16ª Conferencia Anual Alpha Select de Craig-Hallum el 18 de noviembre de 2025 en Nueva York.
Grace es una biopharma de late-stage que avanza GTx-104, una formulación inyectable de nimodipina para infusión IV para tratar a pacientes con hemorragia subaracnoidea aneurismática (aSAH). La Alpha Select Conference es por invitación; las empresas asistentes son seleccionadas por ser compañías públicas más pequeñas y con menor seguimiento, con potencial de escalar. Los inversores que deseen una reunión deben contactar a su representante de Craig-Hallum.
Grace Therapeutics (Nasdaq: GRCE)는 Prashant Kohli CEO가 뉴욕에서 열리는 Craig-Hallum 16th Annual Alpha Select Conference에 2025년 11월 18일에 발표할 것이라고 발표했습니다.
Grace는 GTx-104를 진행 중인 후기 단계 생명공학 기업으로, IV 주입으로 aneurysmal subarachnoid hemorrhage (aSAH) 환자 치료를 위한 nimodipine 주사형 제형을 개발 중입니다. Alpha Select Conference는 초청장으로만 참가할 수 있으며, 참석 기업은 규모가 작고 주목받지 못하는 공기업 중에서 확장 가능성이 있는 기업들로 선정됩니다. 회의를 희망하는 투자자들은 Craig-Hallum 담당자에게 연락해야 합니다.
Grace Therapeutics (Nasdaq: GRCE) a annoncé que le PDG Prashant Kohli présentera lors de la 16e Alpha Select Conference annuelle de Craig-Hallum le 18 novembre 2025 à New York.
Grace est une biopharma en phase tardive qui fait progresser GTx-104, une formulation injectable de nimodipine pour une perfusion IV visant à traiter les saignements sous-arachnoïdiens aneurysmatiques (aSAH). La Alpha Select Conference est sur invitation uniquement; les entreprises participantes sont sélectionnées pour être des sociétés publiques plus petites, moins suivies, avec un potentiel de montée en puissance. Les investisseurs souhaitant obtenir un rendez-vous doivent contacter leur représentant Craig-Hallum.
Grace Therapeutics (Nasdaq: GRCE) gab bekannt, dass CEO Prashant Kohli auf der 16. Alpha Select Conference von Craig-Hallum am 18. November 2025 in New York präsentieren wird.
Grace ist ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das GTx-104, eine injizierbare Nimodipin-Formulierung für eine IV-Infusion zur Behandlung von aneurysmatischen Subarachnoidalblutungen (aSAH), vorantreibt. Die Alpha Select Conference ist eine Einladungskonferenz; auftretende Unternehmen werden ausgewählt, weil sie kleinere, weniger beachtete börsennotierte Unternehmen mit Potenzial zum Skalieren sind. Investoren, die ein Treffen wünschen, sollten ihren Craig-Hallum-Repräsentanten kontaktieren.
Grace Therapeutics (Nasdaq: GRCE) أعلنت أن الرئيس التنفيذي Prashant Kohli سيقدم في المؤتمر السنوي السادس عشر Alpha Select التابع لكريغ-هالووم في 18 نوفمبر 2025 في نيويورك.
Grace هي شركة أدوية حيوية في مرحلة متقدمة تواصل GTx-104، صيغة nimodipine قابلة للحقن لإعطاءها عن طريق IV Infusion لعلاج مرضى النزف الدماغي تحت العنكبوتي aneurysmal subarachnoid hemorrhage (aSAH). مؤتمر Alpha Select هو دعوة فقط؛ يتم اختيار الشركات المشاركة لكونها شركات عامة أصغر وأقل متابعة مع إمكانات للتوسع. يجب على المستثمرين الراغبين في لقاء الاتصال بممثل Craig-Hallum التابع لهم.
- None.
- None.
PRINCETON, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate/present in the upcoming Craig-Hallum 16th Annual Alpha Select Conference, to be held Tuesday, November 18, 2025 in New York, NY.
Companies attending the Alpha Select Conference have been individually selected by the Craig-Hallum research team and are either currently on or display characteristics that are consistent with the Alpha Select List—an actively researched collection of smaller, underfollowed public companies that Craig-Hallum believes have the potential to become much larger. The Alpha Select list typically consists of sub-
The Alpha Select Conference is invitation only. To request a meeting with Mr. Kohli, please contact your Craig-Hallum representative.
About aneurysmal Subarachnoid Hemorrhage (aSAH)
aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is a relatively uncommon type of stroke (aSAH) that accounts for about
About GTx-104
GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for I.V. infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral I.V. infusion. GTx-104 provides a convenient I.V. delivery of nimodipine in the Intensive Care Unit, potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to oral nimodipine.
About Grace Therapeutics
Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutic’s lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Grace Therapeutics’ lead clinical asset, GTx-104, is an I.V. infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull.
For more information, please visit: www.gracetx.com
For more information, please contact:
Grace Therapeutics Contact:
Prashant Kohli
Chief Executive Officer
Tel: 450-686-4555
Email: info@gracetx.com
www.gracetx.com
Investor Relations:
LifeSci Advisors
Mike Moyer
Managing Director
Phone: 617-308-4306
Email: mmoyer@lifesciadvisors.com
FAQ
When will Grace Therapeutics (GRCE) present at the Craig-Hallum Alpha Select Conference?
What program will Grace Therapeutics discuss at the November 18, 2025 presentation?
How can investors request a meeting with Grace Therapeutics (GRCE) at the Alpha Select Conference?
What type of companies attend the Craig-Hallum Alpha Select Conference?
Will Grace Therapeutics release new clinical data at the November 18, 2025 presentation?
